نتائج البحث

Long-term outcomes of S-1 and oxaliplatin neoadjuvant chemotherapy with total mesorectal excision and lateral lymph node dissection for rectal cancer.

• Authors : Morohashi H; Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki-shi, Aomori, 036-8562, Japan. .; Sakamoto Y

Subjects: Rectal Neoplasms*/Rectal Neoplasms*/Rectal Neoplasms*/therapy ; Rectal Neoplasms*/Rectal Neoplasms*/Rectal Neoplasms*/pathology ; Rectal Neoplasms*/Rectal Neoplasms*/Rectal Neoplasms*/mortality

• Source: BMC gastroenterology [BMC Gastroenterol] 2024 Dec 18; Vol. 24 (1), pp. 456. Date of Electronic Publication: 2024 Dec 18.Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X

تفاصيل العنوان

Short-term and long-term oncological outcomes of chemoradiotherapy for rectal cancer patients with or without oxaliplatin: a propensity score-matched retrospective analysis.

• Authors : Azimi A; Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.; Tabatabaei FS

Subjects: Rectal Neoplasms*/Rectal Neoplasms*/Rectal Neoplasms*/therapy ; Rectal Neoplasms*/Rectal Neoplasms*/Rectal Neoplasms*/pathology ; Rectal Neoplasms*/Rectal Neoplasms*/Rectal Neoplasms*/mortality

• Source: Radiation oncology (London, England) [Radiat Oncol] 2024 Dec 03; Vol. 19 (1), pp. 172. Date of Electronic Publication: 2024 Dec 03.Publisher: BioMed Central Country of Publication: England NLM ID: 101265111 Publication Model: Electronic Cited Medium: Internet ISSN: 1748-717X

تفاصيل العنوان

THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer.

• Authors : Zhou X; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.; Interventional Institute of Zhengzhou University, Zhengzhou, Henan, 450052, China.

Subjects: Cancer-Associated Fibroblasts*/Cancer-Associated Fibroblasts*/Cancer-Associated Fibroblasts*/metabolism ; Cancer-Associated Fibroblasts*/Cancer-Associated Fibroblasts*/Cancer-Associated Fibroblasts*/pathology ; Oxaliplatin*/Oxaliplatin*/Oxaliplatin*/pharmacology

• Source: Molecular cancer [Mol Cancer] 2024 Dec 28; Vol. 23 (1), pp. 282. Date of Electronic Publication: 2024 Dec 28.Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598

تفاصيل العنوان

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

• Authors : NRG Oncology

• Source: A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and

تفاصيل العنوان

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

• Source: A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large

تفاصيل العنوان

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

• Source: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients

تفاصيل العنوان

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

• Authors : Anne Noonan, Principal Investigator

• Source: A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX

تفاصيل العنوان

2 Versus 6 Hour Oxaliplatin Infusions in Patients with Gastrointestinal Cancers

• Authors : Hematology/Oncology Pharmacy Association; University of Pittsburgh; Olumide Gbolahan, Principal Investigator

• Source: Phase II Evaluation of the Effect of 2 Versus 6 Hour Oxaliplatin Infusions on Neuropathy and Pharmacokinetics in Patients with Gastrointestinal Cancers

تفاصيل العنوان

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

• Source: A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

تفاصيل العنوان

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

• Authors : Hirschfeld Oncology

• Source: Ph 2 Trial of G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan & Oxaliplatin), Followed by G-FLIP-DM (G-FLIP + Low Doses Docetaxel & MitomycinC), When Used in

تفاصيل العنوان